Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 31 2025
0mins
Should l Buy INTS?
Source: PRnewswire
Investment Announcement: Intensity Therapeutics has entered a securities purchase agreement for the sale of 5 million shares of common stock at $0.80 per share, aiming to raise approximately $4 million to fund clinical trials and general corporate purposes.
Clinical Development: The company is advancing its novel cancer therapy, INT230-6, which has shown promise in killing tumors and eliciting immune responses, with ongoing clinical trials including a Phase 3 study in soft tissue sarcoma and a Phase 2 study in triple-negative breast cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INTS
Wall Street analysts forecast INTS stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.371
Low
1.50
Averages
3.33
High
5.00
Current: 0.371
Low
1.50
Averages
3.33
High
5.00
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intensity Therapeutics Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split Impact: Intensity Therapeutics announced a 1-for-25 reverse stock split aimed at increasing the per-share trading price to comply with Nasdaq listing requirements, reducing outstanding shares from approximately 63.3 million to about 2.5 million, which is expected to help regain compliance with Nasdaq's minimum bid price.
- Weak Stock Performance: Despite broader market gains, with the S&P 500 up 0.24%, the company's stock plummeted 26.70% to $0.27, nearing its 52-week low of $0.18, indicating that company-specific factors are adversely affecting its performance.
- Technical Analysis Signals: The stock is currently trading 30.8% below its 20-day simple moving average and 36.1% below its 50-day simple moving average, indicating significant short-term weakness; however, with an RSI of 46.41 in neutral territory and a MACD above its signal line, there are mixed momentum signals.
- Future Earnings Outlook: The upcoming earnings report on March 12, 2026, is anticipated to be a major catalyst, with an EPS estimate of a loss of 5 cents, an improvement from a loss of 22 cents year-over-year, although revenue is projected at zero, highlighting ongoing challenges in profitability.
See More
Intensity Therapeutics Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split Plan: Intensity Therapeutics has announced a 1-for-25 reverse stock split approved by its board and shareholders, aimed at boosting the per-share price to meet Nasdaq's minimum listing requirements, set to take effect on February 18, consolidating every 25 existing shares into one.
- Trading Change Details: Following the reverse split, Intensity Therapeutics stock will begin trading on February 19 under the new CUSIP number 45828J 202 while retaining the ticker symbol INTS, which will alter the share structure for investors.
- Market Reaction: Following the announcement, Intensity Therapeutics stock traded nearly 30% lower in Friday's premarket, indicating a negative market reaction to the company's price adjustment, which may affect investor confidence.
- Compliance Pressure: This reverse stock split reflects the compliance pressures faced by the company, as failure to meet Nasdaq's listing standards could lead to delisting, thereby impacting the company's ability to raise capital and its market image.
See More
Intensity Therapeutics Announces Reverse Stock Split Plan
- Reverse Stock Split: Intensity Therapeutics announced a 1-for-25 reverse stock split effective February 19, 2026, aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing compliance.
- Shareholder Impact: The reverse split will reduce the outstanding shares from approximately 63,346,579 to about 2,533,863, which, while not affecting the total authorized shares, will alter the shareholding structure and may influence shareholder investment decisions.
- Trading Details: The reverse split will take effect at 4:01 PM ET on February 18, 2026, with shareholders not required to take action for electronic holdings, while those with physical certificates will receive instructions from the transfer agent for share exchange.
- Clinical Progress: Intensity's lead candidate INT230-6 has demonstrated promising anti-cancer effects in multiple clinical trials, which is expected to enhance the company's market performance and investor confidence, further solidifying its position in the biotechnology sector.
See More
Intensity Therapeutics Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split: Intensity Therapeutics announced a 1-for-25 reverse stock split effective February 19, 2026, aimed at increasing the per-share trading price to comply with Nasdaq's minimum bid price requirement, thereby ensuring continued listing eligibility.
- Shareholder Approval: The reverse split plan was approved at a special shareholder meeting on October 22, 2025, and is expected to reduce the outstanding shares from approximately 63,346,579 to about 2,533,863, significantly decreasing the share count to enhance per-share value.
- No Action Required: Shareholders holding shares in electronic book-entry form will not need to take any action as their holdings will be automatically adjusted, while those with physical stock certificates will receive instructions from the transfer agent for share exchange, ensuring a smooth transition.
- Clinical Trial Progress: Intensity's lead product candidate INT230-6 has completed two clinical studies involving over 200 patients, demonstrating its potential in tumor killing and immune system activation, which could shift the treatment paradigm for cancer therapies.
See More
Intensity Therapeutics Inc. Board Greenlights 1-for-25 Reverse Stock Split
- Approval of Stock Split: INTENSITY THERAPEUTICS has received approval from the Board for a 1-for-25 reverse stock split.
- Impact on Shareholders: The reverse stock split is intended to increase the per-share price of the company's stock, potentially attracting more investors.
See More
Intensity Therapeutics Highlights 2025 Milestones and 2026 Strategic Priorities
- Clinical Validation: Intensity Therapeutics' peer-reviewed publication in BioMedicine confirms the clinical potential of INT230-6, reinforcing the company's scientific foundation in cancer treatment and providing robust support for future capital operations and clinical trials.
- Successful Capital Raising: The company has successfully raised funds, ensuring sufficient capital to support its R&D projects, expected to continue into 2027, which not only enhances financial stability but also lays the groundwork for long-term shareholder value creation.
- Clinical Trial Progress: INT230-6 has completed two clinical studies involving over 200 patients and has initiated a Phase 3 trial for soft tissue sarcoma, demonstrating its potential in treating refractory cancers and possibly transforming the cancer treatment landscape.
- Strategic Priorities: The company plans to focus on generating high-quality clinical data and additional peer-reviewed publications in 2026 while enhancing regulatory engagement to ensure market access and long-term success for its products.
See More
Intensity Therapeutics Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split Impact: Intensity Therapeutics announced a 1-for-25 reverse stock split aimed at increasing the per-share trading price to comply with Nasdaq listing requirements, reducing outstanding shares from approximately 63.3 million to about 2.5 million, which is expected to help regain compliance with Nasdaq's minimum bid price.
- Weak Stock Performance: Despite broader market gains, with the S&P 500 up 0.24%, the company's stock plummeted 26.70% to $0.27, nearing its 52-week low of $0.18, indicating that company-specific factors are adversely affecting its performance.
- Technical Analysis Signals: The stock is currently trading 30.8% below its 20-day simple moving average and 36.1% below its 50-day simple moving average, indicating significant short-term weakness; however, with an RSI of 46.41 in neutral territory and a MACD above its signal line, there are mixed momentum signals.
- Future Earnings Outlook: The upcoming earnings report on March 12, 2026, is anticipated to be a major catalyst, with an EPS estimate of a loss of 5 cents, an improvement from a loss of 22 cents year-over-year, although revenue is projected at zero, highlighting ongoing challenges in profitability.
See More
Intensity Therapeutics Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split Plan: Intensity Therapeutics has announced a 1-for-25 reverse stock split approved by its board and shareholders, aimed at boosting the per-share price to meet Nasdaq's minimum listing requirements, set to take effect on February 18, consolidating every 25 existing shares into one.
- Trading Change Details: Following the reverse split, Intensity Therapeutics stock will begin trading on February 19 under the new CUSIP number 45828J 202 while retaining the ticker symbol INTS, which will alter the share structure for investors.
- Market Reaction: Following the announcement, Intensity Therapeutics stock traded nearly 30% lower in Friday's premarket, indicating a negative market reaction to the company's price adjustment, which may affect investor confidence.
- Compliance Pressure: This reverse stock split reflects the compliance pressures faced by the company, as failure to meet Nasdaq's listing standards could lead to delisting, thereby impacting the company's ability to raise capital and its market image.
See More
Intensity Therapeutics Announces Reverse Stock Split Plan
- Reverse Stock Split: Intensity Therapeutics announced a 1-for-25 reverse stock split effective February 19, 2026, aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing compliance.
- Shareholder Impact: The reverse split will reduce the outstanding shares from approximately 63,346,579 to about 2,533,863, which, while not affecting the total authorized shares, will alter the shareholding structure and may influence shareholder investment decisions.
- Trading Details: The reverse split will take effect at 4:01 PM ET on February 18, 2026, with shareholders not required to take action for electronic holdings, while those with physical certificates will receive instructions from the transfer agent for share exchange.
- Clinical Progress: Intensity's lead candidate INT230-6 has demonstrated promising anti-cancer effects in multiple clinical trials, which is expected to enhance the company's market performance and investor confidence, further solidifying its position in the biotechnology sector.
See More
Intensity Therapeutics Announces 1-for-25 Reverse Stock Split
- Reverse Stock Split: Intensity Therapeutics announced a 1-for-25 reverse stock split effective February 19, 2026, aimed at increasing the per-share trading price to comply with Nasdaq's minimum bid price requirement, thereby ensuring continued listing eligibility.
- Shareholder Approval: The reverse split plan was approved at a special shareholder meeting on October 22, 2025, and is expected to reduce the outstanding shares from approximately 63,346,579 to about 2,533,863, significantly decreasing the share count to enhance per-share value.
- No Action Required: Shareholders holding shares in electronic book-entry form will not need to take any action as their holdings will be automatically adjusted, while those with physical stock certificates will receive instructions from the transfer agent for share exchange, ensuring a smooth transition.
- Clinical Trial Progress: Intensity's lead product candidate INT230-6 has completed two clinical studies involving over 200 patients, demonstrating its potential in tumor killing and immune system activation, which could shift the treatment paradigm for cancer therapies.
See More
Intensity Therapeutics Inc. Board Greenlights 1-for-25 Reverse Stock Split
- Approval of Stock Split: INTENSITY THERAPEUTICS has received approval from the Board for a 1-for-25 reverse stock split.
- Impact on Shareholders: The reverse stock split is intended to increase the per-share price of the company's stock, potentially attracting more investors.
See More
Intensity Therapeutics Highlights 2025 Milestones and 2026 Strategic Priorities
- Clinical Validation: Intensity Therapeutics' peer-reviewed publication in BioMedicine confirms the clinical potential of INT230-6, reinforcing the company's scientific foundation in cancer treatment and providing robust support for future capital operations and clinical trials.
- Successful Capital Raising: The company has successfully raised funds, ensuring sufficient capital to support its R&D projects, expected to continue into 2027, which not only enhances financial stability but also lays the groundwork for long-term shareholder value creation.
- Clinical Trial Progress: INT230-6 has completed two clinical studies involving over 200 patients and has initiated a Phase 3 trial for soft tissue sarcoma, demonstrating its potential in treating refractory cancers and possibly transforming the cancer treatment landscape.
- Strategic Priorities: The company plans to focus on generating high-quality clinical data and additional peer-reviewed publications in 2026 while enhancing regulatory engagement to ensure market access and long-term success for its products.
See More
